Decoding biology, one molecule at a time

Our mission is to implement technology that enables the discovery of new disease biomarkers, accelerates the development of therapeutics, and transforms the future of clinical nutrition.

Our mission is to transform healthcare outcomes by pioneering molecular technologies that unlock new frontiers in disease understanding and treatment.

Statistics

Company overview

Clients

8

Completed Projects

18

Newly discovered molecules

20

Active countries

12
Roadmap

Our Story

2018

Innovation inception

The Rizzo lab at EPFL secures $4M+ in research grants to develop and integrate cryogenic infrared ion spectroscopy (CIRIS) with mass spectrometry and advanced separation technologies.

2022

From lab to market

Isospec starts with non-dilutive funding and emerges as an EPFL spin-off.

2023

Isospec goes global

Isospec's pioneering advanced molecular identification services serves customers across 3 continents.

2024

Expanding horizons

Isospec raises $1.9M pre-seed round to revolutionize biomarker research and the development of precision therapeutics.

Media coverage

The minds behind the mission

Isospec unites top-tier scientists with software engineers, machine learning specialists, and biomarker experts. From cutting-edge technologies to AI, we are crafting to tools that will shape tomorrow’s breakthroughs.

Supported by

Enhance your research

Get in touch

Let’s discuss how our team can help you unlock critical insights and fast track your success. Use the calendar to book a meeting with our scientists.

If you have questions, please use the contact form to direct them to our experts.

Let’s discuss how our team can help you unlock critical insights and fast track your success. Use the calendar to book a meeting with our scientists.

If you have questions, please use the contact form to direct them to our experts.